Pharmacokinetic Characteristics and Biodistribution of Radioiodinated Chimeric TNT-1, -2, and -3 Monoclonal Antibodies After Chemical Modification with Biotin

No abstract is available for this paper.

• Publication year

  2002

• Venue

  Cancer Biotherapy and Radiopharmaceuticals

• Publication date

  2002-08-01

• Fields of study

  Medicine, Chemistry

• Identifiers
  DOI 10.1089/108497802760363150PMID 12396700
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Tumor Targeting Properties of Indium-111 Labeled Genetically Engineered Fab′ and F(ab′)2 Constructs of Chimeric Tumor Necrosis Treatment (chTNT)-3 Antibody

  2003cited by this paper
• Biotinylation, Pharmacokinetics, and Extracorporeal Adsorption of Humanized MAb 111In-MN14 Using an Avidin-Affinity Column in Rats

  2003cited by this paper
• Chimeric TNT-3 Antibody/Murine Interferon-γ Fusion Protein for the Immunotherapy of Solid Malignancies

  2003cited by this paper
• Negatively charged polymers protect antinuclear antibody against inactivation by acylating agents.

  2001cited by this paper
• Single amino acid substitution in the Fc region of chimeric TNT-3 antibody accelerates clearance and improves immunoscintigraphy of solid tumors.

  2000cited by this paper
• Favorable effects of glycolate conjugation on the biodistribution of humanized antiTac Fab fragment.

  1999cited by this paper
• The pharmacokinetic characteristics of glycolated humanized anti-Tac Fabs are determined by their isoelectric points.

  1999cited by this paper
• A New Chemically Modified Chimeric TNT-3 Monoclonal Antibody Directed Against DNA for the Radioimmunotherapy of Solid Tumors

  1998cited by this paper
• Improving monoclonal antibody pharmacokinetics via chemical modification.

  1998cited by this paper
• Exploration of novel strategies to enhance monoclonal antibodies targeting.

  1997cited by this paper
• Chimeric CLL-1 antibody fusion proteins containing granulocyte-macrophage colony-stimulating factor or interleukin-2 with specificity for B-cell malignancies exhibit enhanced effector functions while retaining tumor targeting properties.

  1997influential reference
• Modification with Synthetic Polymers

  1996cited by this paper
• Radioimmunotherapy: recent results and future directions.

  1996cited by this paper
• Improved Tumor Localization and Radioimaging with Chemically Modified Monoclonal Antibodies

  1996cited by this paper
• Noninvasive localization of experimental atherosclerotic lesions with mouse/human chimeric Z2D3 F(ab')2 specific for the proliferating smooth muscle cells of human atheroma. Imaging with conventional and negative charge-modified antibody fragments.

  1995cited by this paper
• The functional effects of biotinylation of anti-angiotensin-converting enzyme monoclonal antibody in terms of targeting in vivo.

  1995cited by this paper
• Modification of mouse IgG isoelectric point following radioiodination

  1994cited by this paper
• Technetium-99m-labeled monoclonal antibodies: influence of technetium-99m binding sites.

  1994cited by this paper
• Immunologic and Biochemical Analysis of TNT-1 and TNT-2 Monoclonal Antibody Binding to Histones

  1993cited by this paper
• Improved immunotargeting of tumors with biotinylated monoclonal antibodies and radiolabeled streptavidin

  1993cited by this paper
• Uses and Limitations of Monoclonal Antibodies (MoAbs) in the Treatment of Malignant Disease: A Review

  1993cited by this paper
• Rapid PCR-cloning of full-length mouse immunoglobulin variable regions.

  1991cited by this paper
• Gamma imaging with negatively charge-modified monoclonal antibody: modification with synthetic polymers.

  1991cited by this paper
• Rapid PCR-Cloning of Full-Length Mouse Immunoglobulin Variable Regions

  1991cited by this paper
• Cell based radioimmunoassays to quantitate the immunoreactivity of TNT monoclonal antibodies directed against intracellular antigens.

  1991cited by this paper
• Radioimmunodetection of necrotic lesions in human tumors using I-131 labeled TNT-1 F(ab')2 monoclonal antibody

  1991cited by this paper
• The Research Magnificent

  1990cited by this paper
• A novel method for the detection of necrotic lesions in human cancers.

  1988cited by this paper
• Surface Charge of Resident, Elicited, and Activated Mouse Peritoneal Macrophages

  1987cited by this paper
• The effect of pH on the aggregation of biotinylated antibodies and on the signal-to-noise observed in immunoassays utilizing biotinylated antibodies.

  1987cited by this paper
• The rapid determination of binding constants for antiviral antibodies by a radioimmunoassay. An analysis of the interaction between hybridoma proteins and influenza virus.

  1979cited by this paper
• INDUCTION OF RABBIT ANTIBODY WITH MOLECULAR UNIFORMITY AFTER IMMUNIZATION WITH GROUP C STREPTOCOCCI

  1970cited by this paper
• [74] Spectrophotometric determination of avidin and biotin

  1970influential reference

• Convolutional Neural Networks Guided Raman Spectroscopy as a Process Analytical Technology (PAT) Tool for Monitoring and Simultaneous Prediction of Monoclonal Antibody Charge Variants

  2024cites this paper
• Highly purified charge variants of a proposed biosimilar to Omalizumab: impact on in vitro potency and stability under thermal stress

  2023cites this paper
• Utilizing cross-product prior knowledge to rapidly de-risk chemical liabilities in therapeutic antibody candidates

  2022cites this paper
• Cancer Imaging with Radiolabeled Monoclonal Antibodies

  2020cites this paper
• On-site fabrication of injectable 131I-labeled microgels for local radiotherapy.

  2020cites this paper
• Updated developments on molecular imaging and therapeutic strategies directed against necrosis

  2019cites this paper
• Bevacizumab Radioimmunotherapy (RIT) with Accelerated Blood Clearance Using the Avidin Chase.

  2018cites this paper
• Radioimmunoconjugates for treating cancer: recent advances and current opportunities

  2017cites this paper
• Integrated Chromatographic Platform for Simultaneous Separation of Charge Variants and Aggregates from Monoclonal Antibody Therapeutic Products.

  2017cites this paper
• Main Quality Attributes of Monoclonal Antibodies and Effect of Cell Culture Components

  2017cites this paper
• Charge Variants of an Avastin Biosimilar Isolation, Characterization, In Vitro Properties and Pharmacokinetics in Rat

  2016cites this paper
• Systemic delivery of chTNT-3/CpG immunoconjugates for immunotherapy in murine solid tumor models

  2016cites this paper
• Charge-mediated influence of the antibody variable domain on FcRn-dependent pharmacokinetics

  2015cites this paper
• Necrosis Avidity of Organic Compounds: A Natural Phenomenon with Exploitable Theragnostic Potentials

  2015cites this paper
• Effect of temperature shift on levels of acidic charge variants in IgG monoclonal antibodies in Chinese hamster ovary cell culture.

  2015cites this paper
• Protein comparability assessments and potential applicability of high throughput biophysical methods and data visualization tools to compare physical stability profiles

  2014cites this paper
• Modeling approach to investigate the effect of neonatal Fc receptor binding affinity and anti-therapeutic antibody on the pharmacokinetic of humanized monoclonal anti-tumor necrosis factor-α IgG antibody in cynomolgus monkey.

  2014cites this paper
• Antibody biodistribution coefficients

  2013cites this paper
• Small Molecule Sequential Dual-Targeting Theragnostic Strategy (SMSDTTS): from Preclinical Experiments towards Possible Clinical Anticancer Applications

  2013cites this paper
• Cytoreductive Chemotherapy Improves the Biodistribution of Antibodies Directed against Tumor Necrosis in Murine Solid Tumor Models

  2013cites this paper
• Necrosis Avidity: A Newly Discovered Feature of Hypericin and its Preclinical Applications in Necrosis Imaging

  2013cites this paper
• Chromatographic analysis of the acidic and basic species of recombinant monoclonal antibodies

  2012cites this paper
• Differential Effects of Predosing on Tumor and Tissue Uptake of an 111In-Labeled Anti-TENB2 Antibody–Drug Conjugate

  2012cites this paper
• Minipig as a potential translatable model for monoclonal antibody pharmacokinetics after intravenous and subcutaneous administration

  2012cites this paper
• A review on various targeted anticancer therapies

  2012cites this paper
• Targeted radioimmunotherapy: the role of ¹³¹I-chTNT-1/B mAb (Cotara) for treatment of high-grade gliomas.

  2012cites this paper
• Immunotherapy of brain tumors.

  2012cites this paper
• Convection-enhanced delivery of 131I-chTNT-1/B mAB for treatment of high-grade adult gliomas

  2011cites this paper
• Charge variants in IgG1

  2010cites this paper
• Pharmacokinetic, pharmacodynamic and immunogenicity comparability assessment strategies for monoclonal antibodies.

  2010cites this paper
• Clinical Update: Treatment of Glioblastoma Multiforme with Radiolabeled Antibodies that Target Tumor Necrosis

  2010cites this paper
• Effects of charge on antibody tissue distribution and pharmacokinetics.

  2010cites this paper
• Modifications d'anticorps et de protéines de fusion fc présentant une persistance accrue ou une stabilité pharmacocinétique in vivo et leurs procédés d'utilisation

  2008cites this paper
• Targeting to tumor necrotic regions with biotinylated antibody and streptavidin modified liposomes.

  2008cites this paper
• In vivo Targeting of Dead Tumor Cells in a Murine Tumor Model Using a Monoclonal Antibody Specific for the La Autoantigen

  2007cites this paper
• Phase I Study of 131I-Chimeric(ch) TNT-1/B Monoclonal Antibody for the Treatment of Advanced Colon Cancer

  2006cites this paper
• 131I-chTNT-1/B mAb: tumour necrosis therapy for malignant astrocytic glioma

  2006cites this paper
• Safety and Feasibility of Convection-enhanced Delivery of Cotara for the Treatment of Malignant Glioma: Initial Experience in 51 Patients

  2005cites this paper
• Improved Tumor Targeting by Combined Use of Two Antitenascin Antibodies

  2005cites this paper
• Monoclonal antibodies for brain tumour treatment

  2004cites this paper
• Biotinylation, Pharmacokinetics, and Extracorporeal Adsorption of Humanized MAb 111In-MN14 Using an Avidin-Affinity Column in Rats

  2003cites this paper
• Chimeric TNT-3 Antibody/Murine Interferon-γ Fusion Protein for the Immunotherapy of Solid Malignancies

  2003cites this paper
• Chimeric TNT-3 antibody/murine interferon-gamma fusion protein for the immunotherapy of solid malignancies.

  2003cites this paper
• Tumor Targeting Properties of Indium-111 Labeled Genetically Engineered Fab′ and F(ab′)2 Constructs of Chimeric Tumor Necrosis Treatment (chTNT)-3 Antibody

  2003cites this paper
• A Phase I safety and imaging study using radiofrequency ablation (RFA) followed by 131 I

  2003cites this paper